Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study [0.03%]
维奈克拉联合阿扎胞苷治疗化疗后分子复发的NPM1或CBF急性髓系白血病（AML）：FILO研究
Jules Higué,Corentin Orvain,Pierre-Yves Dumas et al.
Jules Higué et al.
Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms [0.03%]
不适合患者的急性髓系白血病初始治疗算法（2026年版）
Naseema Gangat,Courtney D Dinardo
Naseema Gangat
Management paradigms for newly-diagnosed acute myeloid leukemia (ND-AML) in patients considered unfit to receive intensive chemotherapy have evolved with improved understanding of disease biology. In this setting, management requires clear ...
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma [0.03%]
达鲁莫单抗耐药对接受CAR-T细胞治疗的复发难治多发性骨髓瘤患者临床结局的影响
T Sebastian,S Rajeeve,T Farzana et al.
T Sebastian et al.
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults [0.03%]
成人急性淋巴细胞白血病TP53基因突变的临床和分子特征分析
Ethan J Harris,Diren Arda Karaoglu,Madina Sukhanova et al.
Ethan J Harris et al.
TP53-mutant acute lymphoblastic leukemia (ALL) in adults is a high-risk subtype with poor outcomes, yet its molecular landscape and clinical implications remain incompletely defined. In this multi-institutional study of 830 adult ALL patien...
Genomic and immunogenomic profiling of extramedullary acute myeloid leukemia reveals actionable clonal branching and frequent immune editing [0.03%]
急性髓系白血病的基因组和免疫基因组特征显示可操作的克隆分支和频繁的免疫编辑现象
Clément Collignon,Tucker Hansen,Colin Hercus et al.
Clément Collignon et al.
GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series [0.03%]
靶向GPRC5D双特异性抗体Talquetamab诱导的头晕共济失调综合征的临床表现和处理--系列病例报告
Murali Janakiram,Lawrence Liu,Scott Goldsmith et al.
Murali Janakiram et al.
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts [0.03%]
套细胞淋巴瘤3B亚组结局不同：前瞻性多中心MER和LEO队列研究结果
Patrizia Mondello,Brianna Negaard,Andrew L Feldman et al.
Patrizia Mondello et al.
Follicular lymphoma (FL) 3B is considered an aggressive lymphoma, however recent studies have challenged this paradigm. Additional controversy involves the clinical implication of pure FL3B (FL3Bp) vs FL3B with concurrent diffuse large B ce...
Multicenter Study
Blood cancer journal. 2025 Aug 8;15(1):134. DOI:10.1038/s41408-025-01347-0 2025
Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis [0.03%]
可用电泳检测单克隆蛋白的多发性骨髓瘤中血清游离轻链检测的价值：评估反应和疾病进展
Elham Askari,Angela Dispenzieri,Francis K Buadi et al.
Elham Askari et al.
Uniform assessment of response to treatment is crucial to managing multiple myeloma (MM) and developing new therapies. Measurement of monoclonal protein forms the cornerstone of disease assessment in MM. According to International Myeloma W...
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera [0.03%]
中性粒细胞与淋巴细胞比率可作为真性红细胞增多症JAK2V617F抑制和无事件生存期的替代指标
Tiziano Barbui,Arianna Ghirardi,Victoria Empson et al.
Tiziano Barbui et al.
Chronic systemic inflammation is a key driver of polycythemia vera (PV) progression, but the immunomodulatory effects of current treatments remain poorly defined. The neutrophil-to-lymphocyte ratio (NLR) is an accessible biomarker of system...
Co-occurrence of clonally related follicular lymphoma and histiocytic sarcoma [0.03%]
滤泡性淋巴瘤和组织细胞肉瘤的克隆相关共存现象
Sarah Haebe,Debra K Czerwinski,Anuja Sathe et al.
Sarah Haebe et al.